Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Serina Therapeutics (SER) Interest & Investment Income (2018 - 2022)

Serina Therapeutics' Interest & Investment Income history spans 5 years, with the latest figure at -$863000.0 for Q2 2022.

  • For Q2 2022, Interest & Investment Income fell 214.96% year-over-year to -$863000.0; the TTM value through Jun 2022 reached -$2.0 million, down 165.0%, while the annual FY2021 figure was -$1.1 million, 171.53% down from the prior year.
  • Interest & Investment Income for Q2 2022 was -$863000.0 at Serina Therapeutics, down from -$571000.0 in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $33000.0 in Q2 2019 and bottomed at -$863000.0 in Q2 2022.
  • The 5-year median for Interest & Investment Income is -$90500.0 (2020), against an average of -$173812.5.
  • The largest annual shift saw Interest & Investment Income increased 22.22% in 2019 before it plummeted 1687.5% in 2020.
  • A 5-year view of Interest & Investment Income shows it stood at $32000.0 in 2018, then plummeted by 175.0% to -$24000.0 in 2019, then plummeted by 383.33% to -$116000.0 in 2020, then tumbled by 154.31% to -$295000.0 in 2021, then tumbled by 192.54% to -$863000.0 in 2022.
  • Per Business Quant, the three most recent readings for SER's Interest & Investment Income are -$863000.0 (Q2 2022), -$571000.0 (Q1 2022), and -$295000.0 (Q4 2021).